Immuno-oncology promises a revolution in the way we treat cancer. Since the approval of the first checkpoint inhibitors in 2014, and the subsequent approval of the first cellular therapy in 2017, the field of cancer immunotherapy has exploded with numerous ongoing clinical trials. Despite great successes, emerging results suggest that monotherapies are not sufficient to treat many cancer types and it is increasingly clear that combinatorial approaches are needed to target heterogeneous tumors and improve variability in patient response.

This two-day symposium will convene leading experts in cancer immunotherapy to discuss cutting-edge findings in the broad area of combination therapies, including checkpoint inhibitors and cellular therapies. Particular emphasis will be given to the biological mechanisms underlying combination hypotheses, bispecific antibodies and other emerging modalities for delivery of combination therapies, as well as a discussion of the importance of biomarkers and effective clinical trial design.

Frontiers in Cancer Immunotherapy

Immuno-oncology promises a revolution in the way we treat cancer. Since the approval of the first checkpoint inhibitors in 2014, and the subsequent approval of the first cellular therapy in 2017, the field of cancer immunotherapy has exploded with numerous ongoing clinical trials. Despite great successes, emerging results suggest that monotherapies are not sufficient to treat many cancer types and it is increasingly clear that combinatorial approaches are needed to target heterogeneous tumors and improve variability in patient response.

This two-day symposium will convene leading experts in cancer immunotherapy to discuss cutting-edge findings in the broad area of combination therapies, including checkpoint inhibitors and cellular therapies. Particular emphasis will be given to the biological mechanisms underlying combination hypotheses, bispecific antibodies and other emerging modalities for delivery of combination therapies, as well as a discussion of the importance of biomarkers and effective clinical trial design.